Deletion of the Bacillus anthracis capB homologue in Francisella tularensis subspecies tularensis generates an attenuated strain that protects mice against virulent tularaemia

被引:16
|
作者
Michell, Stephen L. [1 ]
Dean, Rachel E. [1 ]
Eyles, Jim E. [1 ]
Hartley, Margaret Gill [1 ]
Waters, Emma [1 ]
Prior, Joann L. [1 ]
Titball, Richard W. [1 ]
Oyston, Petra C. F. [1 ]
机构
[1] Biomed Sci Def Sci & Technol Lab, Salisbury SP4 0JQ, Wilts, England
关键词
COMPLETE GENOME SEQUENCE; LIVE VACCINE STRAIN; SCHU S4; LVS; INFECTION; CAPSULE; AEROSOL; IDENTIFICATION; ENCAPSULATION; ANTIGENS;
D O I
10.1099/jmm.0.018911-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
As there is currently no licensed vaccine against Francisella tularensis, the causative agent of tularaemia, the bacterium is an agent of concern as a potential bioweapon. Although F. tularensis has a low infectious dose and high associated mortality, it possesses few classical virulence factors. An analysis of the F. tularensis subspecies tularensis genome sequence has revealed the presence of a region containing genes with low sequence homology to part of the capBCADE operon of Bacillus anthracis. We have generated an isogenic capB mutant of F. tularensis subspecies tularensis SchuS4 and shown it to be attenuated. Furthermore, using BALB/c mice, we have demonstrated that this capB strain affords protection against significant homologous challenge with the wild-type strain. These data have important implications for the development of a defined and efficacious tularaemia vaccine.
引用
收藏
页码:1275 / 1284
页数:10
相关论文
共 48 条
  • [41] BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: Association of protection with post-vaccination and post-challenge immune responses
    Twine, Susan
    Shen, Hua
    Harris, Gregory
    Chen, Wangxue
    Sjostedt, Anders
    Ryden, Patrik
    Conlan, Wayne
    [J]. VACCINE, 2012, 30 (24) : 3634 - 3645
  • [42] Toll-like receptor 4 (TLR4) does not confer a resistance advantage on mice against low-dose aerosol infection with virulent type A Francisella tularensis
    Chen, WX
    KuoLee, R
    Shen, H
    Bùsa, M
    Conlan, JW
    [J]. MICROBIAL PATHOGENESIS, 2004, 37 (04) : 185 - 191
  • [43] Mucosal Immunization with Live Attenuated Francisella novicida U112ΔiglB Protects against Pulmonary F-tularensis SCHU S4 in the Fischer 344 Rat Model
    Signarovitz, Aimee L.
    Ray, Heather J.
    Yu, Jieh-Juen
    Guentzel, M. N.
    Chambers, James P.
    Klose, Karl E.
    Arulanandam, Bernard P.
    [J]. PLOS ONE, 2012, 7 (10):
  • [44] Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge
    McCormick, Alison A.
    Shakeel, Aisha
    Yi, Chris
    Kaur, Hardeep
    Mansour, Ahd M.
    Bakshi, Chandra Shekhar
    [J]. PLOS ONE, 2018, 13 (04):
  • [45] Mice sublethally infected with Francisella novicida U112 develop only marginal protective immunity against systemic or aerosol challenge with virulent type A or B strains of F-tularensis
    Shen, H
    Chen, WX
    Conlan, JW
    [J]. MICROBIAL PATHOGENESIS, 2004, 37 (02) : 107 - 110
  • [46] Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-gamma receptor deficient mice
    Ellis, John A.
    Martin, Brittany V.
    Waldner, Cheryl
    Dyer, Kimberly D.
    Domachowske, Joseph B.
    Rosenberg, Helene F.
    [J]. VACCINE, 2007, 25 (06) : 1085 - 1095
  • [47] Mice intradermally-inoculated with the intact lipopolysaccharide, but not the lipid A or O-chain, from Francisella tularensis LVS rapidly acquire varying degrees of enhanced resistance against systemic or aerogenic challenge with virulent strains of the pathogen
    Conlan, JW
    Vinogradov, E
    Monteiro, MA
    Perry, MB
    [J]. MICROBIAL PATHOGENESIS, 2003, 34 (01) : 39 - 45
  • [48] Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen
    Conlan, JW
    Shen, H
    Webb, A
    Perry, MB
    [J]. VACCINE, 2002, 20 (29-30) : 3465 - 3471